Neovascular Age-related Macular Degeneration study: IBI302
Official title A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
ClinicalTrials.gov ID: NCT07275840
What this study is testing
What is IBI302?
an investigational intravitreal injectable medicine being studied as a potential treatment for neovascular age-related macular degeneration
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out whether IBI302 works and is safe for treating neovascular AMD.
- Who it's for
- Adults diagnosed with neovascular (wet) age‑related macular degeneration.
- What's involved
- Participants receive an injection of IBI302 into the eye and attend study visits for eye exams and safety checks.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- Have signed an informed consent form before participating in the research.
- Male or female individuals aged 50 or above at the time of signing the informed consent form;
- Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea.
- At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).
You likely can't join if
- According to the investigator's judgment, concomitant ocular diseases/systemic diseases of the study eyes at screening or baseline may lead to...
- The study eye has uncontrollable glaucoma;
- There is an active intraocular or periocular infection or inflammation in either eye;
- The non-study eye has severe visual function disorders;
- Within 90 days before baseline, the study eye had received anti-VEGF treatment;
- Within 90 days before baseline, the study eye had received anti-complement treatment;
See the full eligibility criteria
- Have signed an informed consent form before participating in the research.
- Male or female individuals aged 50 or above at the time of signing the informed consent form;
- Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea.
- At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).
- According to the investigator's judgment, concomitant ocular diseases/systemic diseases of the study eyes at screening or baseline may lead to participants' non-response to the study treatment or confuse the...
- The study eye has uncontrollable glaucoma;
- There is an active intraocular or periocular infection or inflammation in either eye;
- The non-study eye has severe visual function disorders;
- Within 90 days before baseline, the study eye had received anti-VEGF treatment;
- Within 90 days before baseline, the study eye had received anti-complement treatment;
- At any time before baseline, the study eye had received IBI302 treatment;
- Uncontrollable hypertension;
- Glycated hemoglobin (HbA1c) \> 10.0% within 28 days prior to screening;
- Other exclusion criteria set by protocol.
The study team makes the final eligibility decision.
Where it is enrolling
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.